% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ghasemi:309603,
      author       = {D. R. Ghasemi$^*$ and D. Obrecht-Sturm and K. M. Wallgren
                      and M. U. Schuhmann and B. Timmermann$^*$ and S. Rutkowski
                      and U. Schüller and K. Pajtler$^*$},
      title        = {{A} brief history of ependymoma.},
      journal      = {Neuro-Oncology},
      volume       = {nn},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2026-00253},
      pages        = {nn},
      year         = {2026},
      note         = {#EA:B062#LA:B062# / #DKTKZFB26# / #NCTZFB26# / epub},
      abstract     = {Ependymoma represents a biologically and clinically
                      heterogeneous group of glial tumours that arise throughout
                      the whole neuroaxis and in all age groups. Whereas
                      intracranial ependymoma is usually found in children, adults
                      suffer mostly from spinal cord ependymoma. In comparison to
                      other neuro-oncological tumour entities, ependymoma has been
                      largely understudied for decades. However, the recent years
                      resulted in unprecedented progress with regard to the
                      understanding of the biological underpinnings and clinical
                      features of ependymoma. Here, we review the history of
                      ependymoma research with a focus on the development of
                      classification models throughout the years and a discussion
                      of the most important clinical trials that have led to the
                      current therapeutic standard, comprising maximal safe
                      resection and, in most cases, radiotherapy. Critically, the
                      evidence for effective drugs and chemotherapies in
                      ependymoma is still sparse. However, these important
                      questions may be soon addressed with the finalisation of the
                      currently unpublished last generation of multi-institutional
                      trials in Europe (SIOP EP II) and Northern America
                      (ACNS0831). Lastly, we discuss the current challenges in the
                      field of ependymoma research and the necessary next steps
                      towards the goal of findings cures for all types of
                      ependymal tumours.},
      keywords     = {Ependymal tumours (Other) / Ependymoma (Other) / Medical
                      history (Other) / Molecular classification (Other)},
      cin          = {B062 / ED01 / HD01 / HD02},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)ED01-20160331 /
                      I:(DE-He78)HD01-20160331 / I:(DE-He78)HD02-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41619789},
      doi          = {10.1093/neuonc/noag016},
      url          = {https://inrepo02.dkfz.de/record/309603},
}